Momenta Pharmaceuticals, Inc. (MNTA)

[floblu14]

Back to -

September 8th 2014
MOMENTA PHARMACEUTICALS EXERCISES OPTION TO ACQUIRE
NOVEL ANTIBODY PROGRAM FROM ANAPTYSBIO SHM-XEL Platform Successfully Generates Novel Therapeutic Approach to Autoimmune Disease

The target for the antibodies was selected based on Momenta’s research of the complex biology underlying the anti-inflammatory effects of IVIg. As a result of this research, we engaged AnaptysBio to engineer a novel recombinant antibody that targets a specific biological pathway we believe is important for autoimmune diseases

https://www.anaptysbio.com/momenta-pharmaceuticals-exercises-option-to-acquire-novel-antibody-program-from-anaptysbio/

Forward to -

(Poster)Presented at the Annual European Congress of Rheumatology
June 10-13, 2015 -Momenta Pharmaceuticals, Inc., Cambridge, MA; AnaptysBio, San Diego, CA

.... four IgG-blocking anti-FcRn antibodies significantly increased human IgG (IVIG) catabolism when administered to mice transgenic for human FcRn alpha chain and lacking mouse FcRn alpha chain (strain Tg32) (Figure 2). Anti-FcRn antibody #4 had the best overall properties, was chosen for development as an IgG1 aglycosylated therapeutic antibody,
and named M281.

http://www.momentapharma.com/docs/EULAR-poster-68inX35in-FINAL.pdf

We have a hidden GEM in the IVIG program.